{"id":"ulipristal-acetate-open-label","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dysmenorrhea"},{"rate":"5-10%","effect":"Vaginal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the progesterone receptor, ulipristal acetate inhibits the action of progesterone, which is essential for the growth and maintenance of the endometrium. This mechanism of action is thought to be responsible for its contraceptive effects. Additionally, ulipristal acetate has been shown to have antiproliferative effects on endometrial cells, which may contribute to its contraceptive efficacy.","oneSentence":"Ulipristal acetate is a selective progesterone receptor modulator that acts as an antagonist to progesterone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:15.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Emergency contraception"},{"name":"Treatment of moderate to severe symptoms of uterine fibroids"}]},"trialDetails":[{"nctId":"NCT03296098","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive","status":"WITHDRAWN","sponsor":"Premier Research","startDate":"2020-12","conditions":"Contraception, Healthy Female","enrollment":""},{"nctId":"NCT03208985","phase":"PHASE3","title":"A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions","status":"COMPLETED","sponsor":"HRA Pharma","startDate":"2017-05-23","conditions":"Emergency Contraception","enrollment":1270},{"nctId":"NCT00411684","phase":"PHASE3","title":"Safety and Efficacy of CDB-2914 for Emergency Contraception","status":"COMPLETED","sponsor":"HRA Pharma","startDate":"2006-11","conditions":"Emergency Contraception","enrollment":1623},{"nctId":"NCT03342859","phase":"PHASE1","title":"Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned","status":"TERMINATED","sponsor":"Bayer","startDate":"2017-11-16","conditions":"Leiomyoma","enrollment":10},{"nctId":"NCT02634437","phase":"PHASE1","title":"Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-12-01","conditions":"Renal Function","enrollment":19},{"nctId":"NCT03156127","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet","status":"WITHDRAWN","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-05-19","conditions":"Uterine Myoma","enrollment":""},{"nctId":"NCT02465814","phase":"PHASE2","title":"Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06","conditions":"Leiomyoma","enrollment":120},{"nctId":"NCT01156857","phase":"PHASE3","title":"PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","status":"COMPLETED","sponsor":"PregLem SA","startDate":"2010-07","conditions":"Uterine Fibroids","enrollment":209},{"nctId":"NCT01252069","phase":"PHASE3","title":"PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)","status":"COMPLETED","sponsor":"PregLem SA","startDate":"2011-01","conditions":"Uterine Fibroids","enrollment":132},{"nctId":"NCT01642472","phase":"PHASE3","title":"PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","status":"COMPLETED","sponsor":"PregLem SA","startDate":"2012-07","conditions":"Uterine Fibroids","enrollment":64},{"nctId":"NCT01107106","phase":"","title":"Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women","status":"COMPLETED","sponsor":"HRA Pharma","startDate":"2010-05","conditions":"Contraception","enrollment":579}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PGL4001"],"phase":"phase_3","status":"active","brandName":"Ulipristal Acetate - open label","genericName":"Ulipristal Acetate - open label","companyName":"PregLem SA","companyId":"preglem-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ulipristal acetate is a selective progesterone receptor modulator that acts as an antagonist to progesterone. Used for Emergency contraception, Treatment of moderate to severe symptoms of uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}